Bal Pharma (524824) Stock Overview
Manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
524824 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Bal Pharma Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹103.33 |
| 52 Week High | ₹157.90 |
| 52 Week Low | ₹76.30 |
| Beta | 0.20 |
| 1 Month Change | 6.75% |
| 3 Month Change | 25.46% |
| 1 Year Change | -12.76% |
| 3 Year Change | 9.46% |
| 5 Year Change | 133.51% |
| Change since IPO | 923.07% |
Recent News & Updates
Recent updates
Shareholder Returns
| 524824 | IN Pharmaceuticals | IN Market | |
|---|---|---|---|
| 7D | 3.0% | 1.4% | -0.9% |
| 1Y | -12.8% | 13.0% | -0.3% |
Return vs Industry: 524824 underperformed the Indian Pharmaceuticals industry which returned 13% over the past year.
Return vs Market: 524824 underperformed the Indian Market which returned -0.3% over the past year.
Price Volatility
| 524824 volatility | |
|---|---|
| 524824 Average Weekly Movement | 9.8% |
| Pharmaceuticals Industry Average Movement | 6.5% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in IN Market | 9.3% |
| 10% least volatile stocks in IN Market | 4.4% |
Stable Share Price: 524824's share price has been volatile over the past 3 months compared to the Indian market.
Volatility Over Time: 524824's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of Indian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1987 | 868 | Shailesh Siroya | www.balpharma.com |
Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic preparations targeting conditions, such as prostate enlargement, renal calculi, male infertility, and women health, etc. under the Stonex, Ashwamed, Prostowin, Suswas, Menoleap, and Ayursulin brands; anti-hypertensive, anti-lipidemic, and anti-obese products; skin care and bone health products; and cardiac care products under the Secremet and Servace brands.
Bal Pharma Limited Fundamentals Summary
| 524824 fundamental statistics | |
|---|---|
| Market cap | ₹1.63b |
| Earnings (TTM) | ₹72.15m |
| Revenue (TTM) | ₹3.03b |
Is 524824 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 524824 income statement (TTM) | |
|---|---|
| Revenue | ₹3.03b |
| Cost of Revenue | ₹1.58b |
| Gross Profit | ₹1.45b |
| Other Expenses | ₹1.38b |
| Earnings | ₹72.15m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 4.57 |
| Gross Margin | 47.90% |
| Net Profit Margin | 2.38% |
| Debt/Equity Ratio | 194.3% |
How did 524824 perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/14 21:33 |
| End of Day Share Price | 2025/06/13 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bal Pharma Limited is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.